Compare DOMH & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOMH | TIL |
|---|---|---|
| Founded | 1967 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.1M | 52.2M |
| IPO Year | 2010 | 2021 |
| Metric | DOMH | TIL |
|---|---|---|
| Price | $2.02 | $5.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 230.8K | 17.5K |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | ★ 47.42% | N/A |
| EPS Growth | ★ 34.03 | 6.06 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $123,104,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 578.41 | N/A |
| 52 Week Low | $1.91 | $5.67 |
| 52 Week High | $6.27 | $21.64 |
| Indicator | DOMH | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 39.84 | 23.99 |
| Support Level | $1.91 | $5.67 |
| Resistance Level | $3.33 | $7.95 |
| Average True Range (ATR) | 0.16 | 0.27 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 6.48 | 7.38 |
Dominari Holdings Inc is a holding company that, through its various subsidiaries, is engaged in wealth management, investment banking, sales and trading, asset management, and insurance. In addition to capital investment, Dominari provides management support to the executive teams of its subsidiaries, helping them to operate efficiently and reduce costs under a streamlined infrastructure. The Company operates in two reportable business segments: Dominari Financial and Legacy AIkido, with the majority of revenue from Dominari Financial.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.